Recombinant Human Noggin, Insect Cells Derived

Accession Q13253

GeneID 9241

Source Insect Cell

Molecular Weight Approximately 23.0 kDa on SDS-PAGE under reducing conditions, containing 205 amino acids, and a molecular mass about 47.9 kDa homodimer under non-reducing conditions (Molecular size on SDS-PAGE will appear at approximately 50-80 kDa).

AA Sequence QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC

Purity > 95 % by SDS-PAGE and HPLC analyses.

Biological Activity Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 0.04‑0.2 μg/mL in the presence of 50 ng/mL of Recombinant Human BMP‑4.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH7.4, 5% trehalose, 0.02%Tween-20.

Endotoxin Less than 0.1 EU/μg of rHuNoggin, Insect Cell as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Reference 1. Davis SWandCamper SA. 2007. Dev Biol, 305: 145-60.

2. Zhu W, Kim J, Cheng C, et al. 2006. Bone, 39: 61-71.

3. Oxley CD, Rashid R, Goudie DR, et al. 2008. Horm Res, 69: 221-6.

4. Bayramov AV, Eroshkin FM, Martynova NY, et al. 2011. Development, 138: 5345-56.

5. Secondini C, Wetterwald A, Schwaninger R, et al. 2011. PLoS One, 6: e16078.

Background Noggin encoded by the NOG gene, was first isolated from Xenopus, having the function of inducing secondary axis formation in frog embryos. It inhibits TGF-β family ligands and preventing them from binding to their corresponding receptors. Noggin was originally found as a BMP-4 antagonist, and then has been shown to modulate the activities of other BMPs (BMP-2, 7, 13 and 14). Additionally, it has pleiotropic effect, both in early development and later stages. The results of the mouse knockout of noggin suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. In recent report, proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have relation with the mutant of evolutionarily conserved amino acid residues of Noggin. Mature human Noggin shares 99 %, 99 %, 98 %, 97 % and 89 % a.a. sequence identity with mouse, rat, bovine, equine and chicken Noggin, respectively.